# Artemether/Lumefantrine and Vivax Malaria

> **NCT01625871** · PHASE3 · COMPLETED · sponsor: **University of Khartoum** · enrollment: 38 (actual)

## Conditions studied

- Vivax Malaria

## Interventions

- **DRUG:** tablets artemether/lumefantrine

## Key facts

- **NCT ID:** NCT01625871
- **Lead sponsor:** University of Khartoum
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2013-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625871, "Artemether/Lumefantrine and Vivax Malaria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01625871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*